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Introduction: The aim of this investigation was to assess the effect of galantamine, an acetylcholinesterase
inhibitor and allosteric modulator of nicotinic receptors, on brain atrophy in individuals with mild cognitive
impairment (MCI), and to assess effect modification by apolipoprotein E (APOE) genotype.
Methods: We used data from the Galantamine-International-11 (Gal-Int-11) trial, a 24-month, randomized, double
blind, placebo-controlled, flexible-dose (16 to 24 mg daily) study in patients with MCI. Brain magnetic resonance
imaging (MRI), including a 3-dimensional T1-weighted gradient echo volumetric sequence, was performed at
screening and at 24 months. We recorded whole brain and hippocampal volumes, and calculated annual atrophy
rates. Linear regression analysis was used to calculate adjusted mean differences in the rate of whole brain and
hippocampal atrophy, between MCI patients treated with galantamine and with placebo. Additionally, we
performed stratified analyses according to APOE genotype.
Results: Data from 364 MCI patients with 24-month MRI data (galantamine, n = 176; placebo, n = 188) were
included in the volumetric analysis. Subjects treated with galantamine demonstrated a lower rate of whole brain
atrophy compared to those treated with placebo (adjusted mean difference 0.18% per year (95% confidence
interval (CI) 0.04; 0.30)). Stratified analyses according to APOE genotype, showed that this effect was confined to
patients who carried an APOE ε4 allele (adjusted mean difference 0.28% per year (95% CI 0.07; 0.50)). Rates of
hippocampal atrophy did not differ significantly between study groups.
Conclusions: Patients with MCI who were treated with galantamine demonstrated a lower rate of whole brain
atrophy, but not of hippocampal atrophy, over a 24-month treatment period, compared to those treated with
placebo. This protective effect of galantamine on whole brain atrophy rate in MCI was only present in
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Mild cognitive impairment (MCI) is a heterogeneous
syndrome characterized by a level of cognitive function
(typically memory) that is worse than expected based on
age and educational level, but which does not meet clin-
ical criteria for dementia [1]. Patients with MCI have an
increased risk for the development of Alzheimer’s dis-
ease (AD), with up to 15% of these patients progressing
to dementia per year, compared with up to 2% of the nor-
mal older population [2,3]. Magnetic resonance imaging
(MRI) has contributed to our understanding of the brain
changes associated with MCI and AD. Brain atrophy is a
pathologic change characteristic of AD, with results of
cross-sectional and longitudinal brain imaging studies
demonstrating progressive reduction in whole brain vol-
umes and volumes of the amygdala, hippocampus, and
parahippocampal gyrus [4-6]. At a group level, the degree
and rate of medial temporal lobe and brain atrophy in
individuals with MCI is greater than that in normal con-
trols, and less than that in patients with AD [4]. In MCI
subjects a lower brain or hippocampal volume or a higher
rate of brain or hippocampal atrophy is predictive of pro-
gression of MCI to AD [7-9].
Galantamine is an acetylcholinesterase inhibitor and
allosteric modulator of nicotinic receptors [10-12] that
has consistently demonstrated benefits on cognition, glo-
bal functioning, and the ability to perform activities of
daily living in patients with mild to moderate AD
[13-18]. Some preclinical studies suggest that galanta-
mine has neuroprotective effects, the mechanism(s) of
which appears to be independent of cholinesterase in-
hibition and possibly related to alpha-7 nicotinic re-
ceptors and the phosphatidylinositide 3-kinase–Akt
pathway [19]. Since previous studies showed that
MCI patients who carry an apolipoprotein E (APOE)
ε4 allele are at a higher risk of progressing to AD
and show higher rates of whole brain and hippocampal
atrophy, any assessment of the effect of galantamine on
atrophy in MCI should take into account the APOE geno-
type [20,21].
Data from a large clinical trial, conducted from 2001
to 2003, of galantamine effects in MCI were available for
analysis [22]. In this trial, galantamine did not meet the
primary efficacy endpoint; that is, did not reduce the
percentage of subjects who converted from MCI to de-
mentia (Clinical Dementia Rating score ≥1.0) over 2 years.
However, the data from this trial are a robust source of
longitudinal data on treatment effects of galantamine in
patients with MCI. The objective of the current ana-
lysis was to assess the effect of galantamine (com-
pared with placebo) on the rate of total brain and
hippocampal atrophy, using serial MRI in individuals
with MCI, and to assess whether this effect was modified
by APOE genotype.Methods
Study design and subjects
For the current prospective follow-up study, we used data
from MCI patients who participated in the Galantamine-
International-11 (Gal-Int-11) trial (NCT00236431). Gal-
Int-11 was a 24-month, randomized, double-blind, placebo-
controlled clinical trial studying the effect of galantamine
on cognitive decline in subjects with MCI (Johnson &
Johnson Pharmaceutical Research & Development, LLC,
Titusville, NJ, USA) [22]. Patients eligible for participation
in the Gal-Int-11 trial were ≥50 years of age with a history
of cognitive decline but with insufficient impairment in
activities of daily living to meet diagnostic criteria for de-
mentia. Major inclusion criteria included a global Clinical
Dementia Rating score of 0.5, with a memory score ≥0.5
and a delayed recall score ≤10 on the New York University
paragraph recall test [23,24].
In total, 995 eligible patients were randomized (1:1 ratio)
to receive galantamine or placebo for 24 months. Galanta-
mine was administered at a dose of 4 mg twice daily for
1 month, then 8 mg twice daily for 1 month. If well toler-
ated, the dose could be titrated to 12 mg twice daily, but
could be lowered back to 8 mg twice daily after 1 month if
necessary. The dose selected at month 3 (8 mg or 12 mg
twice daily) was fixed for the remainder of the 24-month
study. Subjects in either study group who progressed from
MCI to dementia (defined as a Clinical Dementia Rating
score ≥1.0) were terminated from the double-blind phase
of the study and were eligible for open-label treatment
with galantamine 8 to 12 mg twice daily throughout the
24 months. The study was approved by Independent
Ethics Committees or Institutional Review Boards, listed
in the Appendix, and conducted in accordance with the
Declaration of Helsinki and its subsequent revisions.
Magnetic resonance imaging procedures
The MRI analysis set included 364 subjects (galantamine,
n = 176; placebo, n = 188) who had taken the double-blind
study drug for at least 600 days and had a suitable MRI at
baseline and at 24 months. Also included were data from
subjects who withdrew or started the open-label study
drug but had a 24-month MRI taken at or after day 600
within 30 days of the last dose of double-blind study drug.
Of the 364 subjects, 269 had a reliable whole brain atro-
phy change measurement, and 321 had a reliable hippo-
campal atrophy change measurement.
Patients underwent brain MRI at screening/baseline and
at month 24 on 1.5 T scanners (GE, Philips, or Siemens). A
three-dimensional T1-weighted gradient echo volumetric
sequence (coronal, 1.5 mm slice thickness, 1 mm in-plane
resolution) and a two-dimensional fast fluid-attenuated
inversion recovery sequence (axial, 5 mm contiguous
slice, 1 mm in-plane resolution) were obtained at both
time points. At screening, a T2-weighted sequence also
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month 24 image sets were sent on electronic media to
two image analysis centers that acted as blinded central
readers.
The Dementia Research Group at the National Hospital
for Neurology in Queen Square, London, UK was respon-
sible for reading the whole brain volume and for calculat-
ing the rate of brain atrophy using the brain boundary shift
integral (BBSI) [25]. The rate of brain atrophy (percent
change per year) was calculated as the BBSI for each
individual subject, divided by the time interval in days,
normalized to 1 year (365.25 days). The BBSI uses voxel in-
tensities to determine the total volume through which an
entire boundary of a structure shifts in registered serially
acquired scans.
The same dataset was sent to the Image Analysis Centre
at the VU University Medical Centre, Amsterdam, the
Netherlands for blinded central reading of the hippocam-
pal volume.
Hippocampal volume measurements were performed
using high-resolution T1-weighted images, reformatted
in a plane perpendicular to the long axis of the hippocam-
pus. Follow-up images were registered to the baseline scan.
Using 1.5 mm thick reformatted slices, approximately 20
to 25 slices were used to delineate the hippocampus. All
measurements were obtained on the left and right sides
separately, and were corrected for the size of the intracra-
nial cavity (to account for premorbid differences in brain
size). Hippocampal measurements were performed accord-
ing to the definitions of Jack [26], using the in-house devel-
oped software package Show_Images 3.7.0, as described
previously [27]. The rate of hippocampal atrophy (percent
change per year) was calculated as the linear change of the
hippocampal volume, divided by the time interval in days,
normalized to 1 year (365.25 days).
Raters were blinded to treatment allocation, but
not to the order of scanning. All subjects provided written
informed consent before enrollment. The studies were
approved by an Independent Ethics Committee or
Institutional Review Board and were conducted in ac-
cordance with the Declaration of Helsinki and its sub-
sequent revisions.
Apolipoprotein E genotyping
APOE genotyping was performed as an exploratory
measure in subjects who consented to participate; this
participation was not mandatory for enrollees. Of the
364 subjects in the MRI analysis set, information on the
APOE genotype was available for 274 subjects (75%).
Data analysis
Analyses were performed using SPSS (version 20; SPSS,
Chicago, IL, USA). The MRI analysis set comprised 364
subjects. Of those, 176 received galantamine and 188received placebo. Information on the APOE genotype was
available for 274 patients (APOE noncarriers, n = 145;
APOE carriers, n = 129). We compared baseline character-
istics between patients treated with galantamine (n = 176)
and placebo (n = 188) and between APOE carriers and
APOE noncarriers using Student’s t test for continuous
variables and chi-square tests for nominal variables.
We assessed the associations of age, sex, vascular risk
factors, baseline Alzheimer’s Disease Assessment Scale –
cognitive subscale (ADAS-Cog)/MCI score, and APOE
genotype with whole brain atrophy rate and hippocampal
atrophy rate using linear regression analysis, adjusting for
age and sex.
Of the 364 subjects in the MRI analysis set, 269 had a
reliable whole brain atrophy change measurement and
321 a reliable hippocampal atrophy change measurement.
We calculated age and sex-adjusted mean differences
(95% confidence interval (CI)) in total brain atrophy rate
and hippocampal atrophy rate between patients who re-
ceived galantamine and those who received placebo, using
linear regression analysis. To control for potential con-
founding factors, we added vascular risk factors and base-
line ADAS-Cog/MCI score to the model. We repeated the
analyses after stratification according to APOE genotype.
Furthermore, we calculated age and sex-adjusted mean
differences (95% CI) in total brain atrophy rate and hippo-
campal atrophy rate between APOE ε4 carriers and APOE
ε4 noncarriers.
Results
Table 1 summarizes the baseline demographic and cogni-
tive characteristics of the 364 subjects in the MRI analysis
set, according to treatment group and for the total num-
ber of subjects. The percentage of women in the placebo
group was higher compared with that in the galantamine
group, but there were no other differences in baseline
characteristics between the placebo and galantamine-
treated groups (Table 1). Of the 364 subjects in the MRI
analysis set, 10 (2.7%) converted to dementia. Table 2
summarizes the same baseline characteristics, but only for
the 274 subjects in the MRI analysis set who had available
information on APOE genotype, separate for APOE ε4
carriers and APOE ε4 noncarriers, and for the total num-
ber. MCI patients who were APOE ε4 noncarriers more
often had hypertension and had lower ADAS-Cog/MCI
scores than MCI patients who were APOE ε4 carriers
(Table 2).
The mean whole brain atrophy rate was 0.52% per year
and the mean hippocampal atrophy rate was 1.74% per
year. Older age was associated with higher whole brain
atrophy rate (β per year increase, 0.02% (95% CI, 0.01 to
0.03%)) and higher hippocampal atrophy rate (β per year
increase, 0.05% (95% CI, 0.03 to 0.07%)). Presence of
diabetes was associated with higher whole brain atrophy
Table 1 Baseline characteristics for the total number of








Age 68 (8.8) 69 (8.6) 68 (9.0) 0.13
Sex, female 49 54 43 0.04
Hypertension 44 45 43 0.62
Diabetes 7 7 7 0.98
Elevated cholesterol 34 35 32 0.59
Smoking 9 10 7 0.46
ADAS-Cog/MCI 15 (7.0) 14 (6.9) 15 (7.2) 0.56
Whole brain (ml) 1,089 (124) 1,081 (124) 1,097 (123) 0.22
Hippocampal
volume (ml)
5.85 (0.9) 5.78 (0.9) 5.93 (0.9) 0.11
Data presented as means (standard deviation) or percentages. ADAS-Cog,
Alzheimer’s Disease Assessment Scale – cognitive subscale; MCI, mild cognitive
impairment. aP values for differences in means or percentages between patients
treated with placebo and those treated with galantamine.
Table 3 Whole brain atrophy rates for subjects treated
with placebo and with galantamine





0.63 0.46 0.17 0.04 to 0.30
Hippocampal
atrophy rate
1.70 1.94 −0.24 −0.62 to 0.12
Data presented as percentage change per year. The numbers of subjects per
cell are as follows: whole brain atrophy rate, total n = 242 (placebo, n = 130;
galantamine, n = 112); hippocampal atrophy rate, total n = 302 (placebo, n =
160; galantamine, n = 142). CI, confidence interval.
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hippocampal atrophy rate. Higher ADAS-Cog/MCI score
was associated with higher whole brain atrophy rate (β per
point increase, 0.01% (95% CI, 0.00 to 0.02)) and higher
hippocampal atrophy rate (β, 0.07% (95% CI, 0.04 to
0.10%)). APOE ε4 carriers had higher whole brain atrophy
rates (adjusted mean difference, 0.16% (95% CI, 0.02 to
0.30%)) and hippocampal atrophy rates (adjusted mean
difference, 0.68% (95% CI, 0.28 to 1.07%)) compared with
APOE ε4 noncarriers.
Table 3 presents the difference in whole brain atrophy
rate and hippocampal atrophy rate between subjects
treated with placebo and those treated with galantamine.Table 2 Baseline characteristics for subjects who had










Age 68 (8.9) 69 (8.8) 68 (8.9) 0.76
Sex, female 48 53 44 0.16
Hypertension 44 36 50 0.02
Diabetes 8 8 9 0.72
Cholesterol 34 30 38 0.18
Smoking 8 6 10 0.29
ADAS-Cog/MCI 14 (7.0) 16 (7.4) 13 (6.2) 0.00
Whole
brain (ml)
1,088 (122) 1,083 (110) 1,092 (132) 0.54
Hippocampal
volume (ml)
5.91 (0.85) 5.83 (0.90) 5.98 (0.83) 0.17
Data presented as means (standard deviation) or percentages. ADAS-Cog,
Alzheimer’s Disease Assessment Scale – cognitive subscale; APOE, apolipoprotein
E; MCI, mild cognitive impairment. aP values for differences in means or
percentages between patients treated with placebo and those treated
with galantamine.Subjects treated with galantamine demonstrated a lower
rate of whole brain atrophy, but not of hippocampal atro-
phy, compared with those treated with placebo (Table 3).
Table 4 presents the difference in whole brain atrophy rate
stratified according to APOE genotype. This stratified ana-
lysis showed that the association between galantamine
treatment and lower whole brain atrophy rate was con-
fined to carriers of an APOE ε4 allele (Table 4). MCI
patients who carried an APOE ε4 allele and were treated
with galantamine showed 36% less whole brain atrophy
compared with those who were treated with placebo. Add-
itional adjustments for vascular risk factors and baseline
ADAS-Cog/MCI score did not change the results (data
not shown). There were no statistically significant
between-group differences in the rate of hippocampal
atrophy after stratification for APOE genotype (data
not shown).
Discussion
In a subset of MCI patients who participated in the
Gal-Int-11 trial and underwent MRI at baseline and
at 24 months, we found that MCI patients who received
galantamine showed lower whole brain atrophy rates com-
pared with those treated with placebo. In subsequent
stratified analyses, we found that this difference was only
present in patients who carried an APOE ε4 allele. We
found no treatment effects on the rate of hippocampal
atrophy. When interpreting these results, one should take
into account that this MRI analysis set did not includeTable 4 Whole brain atrophy rates for subjects treated
with placebo or galantamine, stratified according to
apolipoprotein E genotype





0.48 0.41 0.07 −0.10; 0.25
APOE ε4 carriers 0.77 0.49 0.28 0.07; 0.50
Data presented as percentage change per year. The numbers of subjects per
cell were as follows: APOE ε4 noncarriers, total n = 109 (placebo, n = 54;
galantamine, n = 55), APOE ε4 carriers, total n = 97 (placebo, n = 54;
galantamine, n = 43). APOE, apolipoprotein E; CI, confidence interval.
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of their 24-month MRI, and that this selective dropout
has contributed to a benign study sample. This explains
why the mean whole brain and hippocampal atrophy rate
were lower compared with other studies in MCI [8,9]. The
study included patients with amnestic MCI, although it is
not possible to rule out the possibility that some patients
had multidomain MCI.
MRI has emerged as a useful tool for the study of MCI
and AD [28]. To date, no study has evaluated the effect
of galantamine on the rate of brain volume in patients
with MCI. The Gal-Int-11 trial used established imaging
techniques [29] and structural boundary definitions
[26,30] for the study of brain morphology. The use of
BBSI to determine the rate of brain atrophy minimized
the impact of any inaccuracies in segmentation and oper-
ator/reader bias [25].
It is unclear why the effects of galantamine were ob-
served on brain volume but not on hippocampal volume.
Variability in hippocampal volume was possibly magni-
fied because of the small volume of the hippocampus,
making the detection of any treatment effect difficult.
The absence of a significant effect on hippocampal vol-
ume might also be attributable to the lack of matching
of the study groups with regard to baseline hippocampal
size or a lack of power to detect a treatment effect for hip-
pocampal atrophy. Alternatively, the effect of galantamine
on brain volume may be explained by a ceiling effect.
We found that galantamine only lowered the rate of
brain atrophy in MCI patients who were APOE ε4
carriers. Compared with noncarriers, these MCI patients
are more likely to have underlying AD pathology; that is,
they are more likely to classify as prodromal AD accord-
ing to the Albert criteria, since APOE ε4 positivity in
MCI has been found to be associated with amyloid posi-
tron emission tomography positivity, and with the AD
biomarker profile in cerebrospinal fluid [31-33]. Our
results suggest that a potential beneficial effect of gal-
antamine on brain atrophy may be restricted to MCI
patients with underlying AD pathology.
Acetylcholinesterase inhibitors have previously been
shown to exhibit a neuroprotective effect via the nic-
otinic acetylcholine receptor-mediated cascade [34,35].
Acetylcholinesterase inhibitors that are not positive
allosteric modulators of nicotinic receptors, however,
have not shown significant effects on brain or hippo-
campal volume loss in placebo-controlled studies of 2
to 4 years’ duration in MCI patients [36,37]. In addition, it
has been reported that acetylcholinesterase inhibitors in-
hibit the progress of brain atrophy in AD, indicating
the attenuation of neuronal death in the brain of the
patients, although in this study the hippocampal atro-
phy rate in AD patients treated with donepezil was
compared with that of historic controls, and not withpatients randomized to placebo in a double-blind
clinical trial [21].
The reduced rate of whole brain atrophy observed in
this trial provides clinical evidence of neuroprotection
with galantamine treatment. Further research is needed to
elucidate the interrelation between the APOE genotype
and a potential neuroprotective effect of galantamine.
Conclusions
Patients with MCI who were treated with galantamine
demonstrated a lower rate of whole brain atrophy, but
not of hippocampal atrophy, over a 24-month treat-
ment period, compared with those treated with placebo.
This protective effect of galantamine on the whole brain
atrophy rate in MCI was only present in APOE ε4
carriers.
Appendix
Independent Ethics Committees or Institutional Review
Boards that approved the Gal-Int-11 trial (NCT00236431)
per country.
Austria
 Ethikkommission d. Med. Fakultät der Universität
Wien, Borschkegasse 8b, A-1090 Wien, Austria
 Ethikkommission der Stadt Wien gem. KAG, AMG
und MPG Stabstelle Pharmazie und Medizinökonomie,
Schottenring 24, A-1010 Wien, Austria
 Ethikkommission der Med. Fakultät der Universität
Innsbruck, Innrain 42, A-6020 Innsbruck, Austria
 Ethikkommission d. Med. Fakultät der Universität
Graz, Auenbruggerplatz 29, A-8036 Graz, Austria
Canada
 The University of Western Ontario Research Ethics
Office, Dental Sciences Building, London, ON,
Canada N6A 5C1
 Comite d’ethique de la recherché Centre
Hospitalier Affilie Universitaire de Quebec Hopital
de l’Enfant-Jesus Nursing, Cognitive Research Nursing
Gerontology Neuropsychology Psychology 1401, 18e
Rue, Quebec, QC, Canada G1J 1Z4
 South East Health Care Corporation Research
Review Committee, 1365 MacBeath Avenue, Moncton,
NB, Canada E1C 6Z8
 University of British Columbia Clinical Research
Ethics Board Office of Research Services Room 210,
Research Pavilion, 828 W. 10th Avenue Vancouver,
BC, Canada V5Z 1L8
 Institutional Review Board, McGill University
Faculty of Medicine, McIntyre Medical Bldg, 3655 Sir
Willam Osler, Room 637, Montreal, QC, Canada
H3G 1Y7
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http://alzres.com/content/6/4/47 Service De Sante, Ethics Research Board SCO
Health Services, 75 Bruyere, Ottawa, ON, Canada
K1N 5C8
 Conjoint Health Research Ethics Board, 3330
Hospital Drive N.W., Calgary, AB, Canada T2N
4N1
 Research Ethics Committee Room 118, Centre for
Clinical Research 5790 University Avenue, Halifax,
NS, Canada B3H 1V7
 University of Alberta, Health Research Ethics Board
2J2.27 WMC, University of Alberta, Edmonton, AB,
Canada T6G 2R7
 Hopital General du Lakeshore General Hospital,
160 Stillview Pointe Claire, QC, Canada H9R 2Y2
 Hopital Maisonneuve-Rosemont, Pavillion
Rachel-Tourigny/Ethics Board, 5415 Blvd. de
l’Assomption, Montreal, QC, Canada,
H1T 2M4
Finland
 Tutkimuseettinen toimikunta KYS Rakennus 2 G
(0-krs), P.O. Box 1777, FIN-70211 Kuopio, Finland
France
 CCPPRB de Rennes CHU Pontchaillou, Pavillon
Clémenceau, 35033 Rennes, France
Germany
 Medical Ethics Committee II of Faculty for Clinical
Medicine, Mannheim Ruprecht-Karls-University
Heidelberg, Maybachstraße 14–16, D-68169
Mannheim, Germany
 Ethics Committee of Free University Berlin,
University Clinic Benjamin Franklin, Hindenburgdamm
30, D-12200 Berlin, Germany
 Ethics Committee of Albert-Ludwigs University
Freiburg, Elsaesser Straße 2m, House 1A,
D-79110 Freiburg, Germany
 Ethics Committee of Medical Faculty of Technical
University Munich, Ismaninger Straße 22,
D-81675 München, Germany
 Ethics Committee of J.W. Goethe University
of Frankfurt/Main Theodor-Stern-Kai 7,
D-60590 Frankfurt/Main, Germany
 Ethics Committee of University Ulm,
Helmholtzstraße 20 (Oberer Eselsberg), D-89081 Ulm,
Germany
 Ethics Committee of Medical Faculty of
Friedrich-Alexander-University Erlangen-Nueremberg,
Universitaetsstraße 40, D-91054 Erlangen,
GermanyThe Netherlands
 Central: METOPP, Beethovenlaan 332a, 5011 LN
Tilburg, the Netherlands
 Local: METC Noord-Holland. Wilhelminalaan 12,
1815 JD Alkmaar, the Netherlands
 Local: METC Noord-Oost Brabant locatie GZG,
kamer L1.143, Tolbrugstraat 11, 5211
RW’s-Hertogenbosch, the Netherlands
 Local: METC West-Brabant, Molengracht 21,
4818 CK Breda, the Netherlands
 Local: Subcommissie voor de ethiek van het
mensgebonden onderzoek, Hoogbouw
2.15 De Boelelaan 1117, 1081HV
Amsterdam, the Netherlands
 Local: MEC azM/UM Attn: Mr. J. Smeets,
secretaris P. Debyelaan 25, 6229 HX
Maastricht, the Netherlands
Poland
 Komisja Etyczna Centralny Szpital Kliniczny
MSWiA, Wołoska 137, 02–507 Warszawa, Poland
 Niezależna Komisja Bioetyczna Do Spraw Badań
Naukowych przy Akademmi Medycznej
w Gdańsku, M. Skłodowskiej–Curie 3a,
80–210 Gdańsk, Poland
 Komisja Bioetyczna Przy Akademii Medycznej im.
Karola Marcinkowskiego w Poznaniu Fredry 10,
61–701 Poznań, Poland
 Uczelniana Komisja Etyki Badań Naukowych Przy
Akademii Medycznej wŁodzi Al. Kościuszki 4,
90–419 Lodz, Poland
 Komisja Bioetyczna Śląskiej Akademii Medycznej
Poniatowskiego 15, 40–055 Katowice, Poland
Sweden
 Research Ethics Committee, University of Umeå,
SE-901 87 Umeå, Sweden
 Research Ethics Committee, University Hospital,
SE-581 85 Linköping, Sweden
 Research Ethics Committee, University Hospital,
SE-221 85 Lund, Sweden
 Research Ethics Committee Arvid Wallgrens Backe
Hus 7, Box 454, SE-405 30 Göteborg, Sweden
 Research Ethics Committee Faculty of Medicine
Karolinska Institute, SE-17177 Stockholm, Sweden
United Kingdom
 MREC (central IEC): Administrator MREC for
Wales BRO TAF Health Authority, Cathays Park,
Cardiff CF10 3NW, UK
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http://alzres.com/content/6/4/47 LREC (local IEC): Southampton and South
West Hants Joint Local Research Ethics Committee,
Trust Management Offices, Southampton
General Hospital, Tremona Road
Southampton SO16 6YD, UK
 LREC (local IEC): Swindon Research Ethics
Committee, Wiltshire Health Authority, Southgate
House, Pans Lane, Devizes SN10 5EQ, UK
 LREC (local IEC): National Waiting Time Centre,
Beardmore Street, Clydebank G81 4HX, UK
 LREC (local IEC): Health Board Research Ethics
Committee, Boswell House, 10 Arthur Street,
Ayr KA7 1OJ, UK
 LREC (local IEC): Bradford Local Research Ethics
Committee, Bradford Royal Infirmary, Duckworth
Lane, Bradford BD9 6RJ, UK
 LREC (local IEC): Local Research Ethics
Committee, North Bristol NHS Trust Head Quarters,
Clincal Governance Directorate Executive Team Base,
Frenchay Hospital, Bristol BS16 1JE, UK
 LREC (local IEC): Southampton and South
West Hants Joint Local Research Ethics
Committee, Trust Management Offices, Southampton
General Hospital, Tremona Road, Southampton
SO16 6YD, UK
USA
 Biomed Research Institute of America, 3110
Camino Del Rio, South Suite A215, San Diego,
CA 92108, USA
 North Broward Medical Center Institutional
Review Board, 201 E. Sample Road, Pompano Beach,
FL 33064, USA
 University of Pittsburgh Review Board, Hieber
Building, 3500 Fifth Avenue, Pittsburgh, PA 15213,
USA
 Biomedical Research Alliance of NY, LLC 225
Community Drive, Suite 100, Great Neck,
NY 11021, USA
 WIRB, 3535 Seventh Avenur Southwest, Olympia,
WA 98502–5010, USA
 Oregon Health and Science University
Institutional Review Board – L106, 3181
SW Sam Jackson Park Road, Portland,
OR 97201–3098, USA
 Institutional Review Board for Human Research,
Office of Research Integrity Medical University
of South Carolina, 165 Cannon Street, Charleston,
SC 29425, USA
 St. John Medical Center Institutional Review Board,
1923 S. Utica Avenue, Tulsa, OK 74104, USA
 University of Texas Health Science Center, 7703
Floyd Curl Drive, San Antonio, TX 78229, USA Butler Hospital, 345 Blackstone Blvd, Providence,
RI 02906, USA
 Office of Research Administration, Rhode Island
Hospital, 593 Eddy Street Providence, RI 02906,
USA
 The Ohio State University Research Foundation,
1960 Kenny Road, Columbus, OH 43210, USA
 Human Research Office Brigham & Women’s
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